^
    Back
    Association details:
    Biomarker:KRAS G12C + TP53 mutation
    Cancer:Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Zhejiang Univ Sci B
    Title:

    USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer

    Published date:
    02/17/2023
    Excerpt:
    Our findings indicated that, USH2A missense mutations and the KRASG12C mutation combined with TP53 mutation were associated with better efficacy and survival outcomes…
    DOI:
    https://doi.org/10.1631/jzus.B2200292